17734-20-2

Usage

Uses

Used in Organic Synthesis:
6-Phenylhexylamine is used as a synthetic intermediate for the production of various organic compounds. Its unique structure allows it to be a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 6-Phenylhexylamine is used as a key intermediate in the synthesis of certain drugs. Its presence in the molecular structure can contribute to the drug's efficacy and pharmacological properties.
Used in Agrochemical Industry:
6-Phenylhexylamine also finds application in the agrochemical industry, where it is used as a precursor for the development of pesticides and other crop protection agents. Its role in these products helps to enhance crop yield and protect against pests.
Used in Specialty Chemicals:
In the specialty chemicals sector, 6-Phenylhexylamine is utilized in the production of various compounds with specific applications, such as dyes, fragrances, and other functional materials. Its versatility in synthesis makes it a valuable component in this industry.

Upstream product

• 10521-91-2 5-phenylpentan-1-ol 
• 56644-06-5 6-phenyl-1-hexylchloride 
• 17734-38-2 ethyl 5-phenylpentanoate 
• 14469-83-1 (5-bromopentyl)benzene 
• 27976-27-8 (6-bromohexyl)benzene 
• 2430-16-2 6-phenyl-1-hexanol 
• 138619-78-0 2-(6-phenylhexyl)-1,3-dihydro-1,3-dioxo-2H-isoindole 
• 17777-31-0 6-phenylhexanenitrile 

Downstream Products

• 143819-12-9 6-phenyl-1-hexyl isocyanate 
• 1072807-18-1 phenylhexylformamide 
• 133920-06-6 Phenylhexyl isothiocyanate 
• 1147130-31-1 N-(6-phenylhexyl)-quinoline-6-carboxamide 
• 98455-86-8 2-[N-(6-phenylhexylamino)]-5-hydroxy-4-methylpyrimidine 
• 135012-80-5 5-Acetylamino-2-(6-phenylhexyl-amino)-tetralinehydrochloride 
• 251478-84-9 2'-(2-hydroxy-ethoxy)-3,3''-bis-trifluoromethyl-[1,1';3',1'']terphenyl-5'-carboxylic acid (6-phenyl-hexyl)-amide 
• 251478-56-5 2'-(2-hydroxy-ethoxy)-4''-methoxy-3-trifluoromethyl-[1,1';3',1'']terphenyl-5'-carboxylic acid (6-phenyl-hexyl)-amide 

Relevant academic research and scientific papers

meta-Selective C?H Borylation of Benzylamine-, Phenethylamine-, and Phenylpropylamine-Derived Amides Enabled by a Single Anionic Ligand

Selective functionalization at the meta position of arenes remains a significant challenge. In this work, we demonstrate that a single anionic bipyridine ligand bearing a remote sulfonate group enables selective iridium-catalyzed borylation of a range of common amine-containing aromatic molecules at the arene meta position. We propose that this selectivity is the result of a key hydrogen bonding interaction between the substrate and catalyst. The scope of this meta-selective borylation is demonstrated on amides derived from benzylamines, phenethylamines and phenylpropylamines; amine-containing building blocks of great utility in many applications.

Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents

The modulation of the endocannabinoid system is emerging as a viable avenue for the treatment of neurodegeneration, being involved in neuroprotective and anti-inflammatory processes. In particular, indirectly enhancing endocannabinoid signaling to therapeutic levels through FAAH inhibition might be beneficial for neurodegenerative disorders such as Alzheimer's disease, effectively preventing or slowing the progression of the disease. Hence, in the search for a more effective treatment for Alzheimer's disease, in this paper, the multitarget-directed ligand paradigm was applied to the design of carbamates able to simultaneously target the recently proposed endocannabinoid system and the classic cholinesterase system, and achieve effective dual FAAH/cholinesterase inhibitors. Among the two series of synthesized compounds, while some derivatives proved to be extremely potent on a single target, compounds 9 and 19 were identified as effective dual FAAH/ChE inhibitors, with well-balanced nanomolar activities. Thus, 9 and 19 might be considered as new promising candidates for Alzheimer's disease treatment.

Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases

Fatty acid amide hydrolase (FAAH, EC 3.5.1.99) is the main enzyme catabolizing endocannabinoid fatty acid amides. FAAH inactivation promotes beneficial effects upon pain and anxiety without the side effects accompanying agonists of type-1 cannabinoid receptors. Aiming at discovering new selective FAAH inhibitors, we developed a series of compounds (5a-u) characterized by a functionalized heteroaromatic scaffold. Particularly, 5c and 5d were identified as extremely potent, noncompetitive, and reversible FAAH inhibitors endowed with a remarkable selectivity profile and lacking interaction with the hERG channels. In vivo antinociceptive activity was demonstrated for 5c, 5d, and 5n at a dose much lower than that able to induce either striatal and limbic stereotypies or anxiolytic activity, thus outlining their potential to turn into optimum preclinical candidates. Aiming at improving pharmacokinetic properties and metabolic stability of 5d, we developed a subset of nanomolar dialyzable FAAH inhibitors (5v-z), functionalized by specific polyethereal lateral chains and fluorinated aromatic rings.

Efficient conversion of primary and secondary alcohols to primary amines

A convenient single-vessel conversion of primary and secondary alcohols to primary amines is reported. Use of this method results in substantially cleaner crude products than similar procedures reported in the literature. A simple work-up also makes this procedure ideal for parallel synthesis.

Condensed compounds, their production and use

This invention provides new condensed furan compounds which exhibit excellent 2,3-oxidosqualene cyclase inhibition and high-density lipoprotein-cholesterol elevating activities. This invention also provides a therapeutic and prophylactic agent for hyperlipidemia, hypercholesterolemia and atherosclerosis.

Monocyclic Pteridine Analogues. Inhibition of Escherichia coli Dihydropteroate Synthase by 6-Amino-5-nitrosoisocytosines

A variety of 5,6-disubstituted isocytosine derivatives were evaluated in vitro as inhibitors of dihydropteroate synthase from Escherichia coli.A number of 6-(alkylamino)-5-nitrosoisocytosines have in vitro potency equivalent with or superior to that of therapeutically effective sulfonamide inhibitors of the synthase.The sulfonamide drugs are known to complete for the p-aminobenzoic acid binding site of the synthase, and kinetic analysis of inhibition of the synthase by 6-(methylamino)-5-nitrosoisocytosine (16; I50 = 1.6 μM) and by the 6-(3-phenoxypropyl)amino analogue (33; I50 = 3.7 μM) indicated that the nitrosoisocytosine inhibitors compete with the pteridine substrate for the enzyme.Structure-activity studies demonstrated that the enzyme surface has a low tolerance for steric bulk in the region surrounding the isocytosine 6-amino function.However, this steric intolerance may be counterbalanced to a significant degree by positive allosteric interactions achieved by certain analogues that have a 6-(ω-phenylalkyl)amino substituent.For example, 6--5-nitrosoisocytosine (28) is as effective an inhibitor (I50 = 1.4 μM) as the 6-methylamino compound 16.Although several members of the 5-nitroso series were potent synthase inhibitors, none of the nitrosoisocytosines exhibited significant antibacterial activity.This observation may reflect poor transport of these compounds through the bacterial cell wall or, alternatively, may result from a rapid metabolic inactivation process.